What is the CHRS stock price prediction for next 2 weeks?

According to our price prediction algorithm,Coherus Oncology, Inc. (CHRS) price will be around $1.43 in the next 2 weeks. This means it will decrease by -3.182432432432427 from the last closing price. This prediction may vary from other time period filters for CHRS stock.

What can be the highest Possible price of CHRS stock in next 2 weeks?

Our forecast algorithm expects that in 2 weeks, CHRS can achieve the highest price of $1.53 which is 3.640582971427733 higher than last closing price. This prediction may vary from other time period filters for CHRS stock.

What can be the lowest Possible price of CHRS stock in next 2 weeks?

As per the forecast and algorithmic analysis, CHRS stock price can be as low as $1.33 which is -9.906908561117653 lower than the current price in the next 2 weeks. This prediction may vary from other time period filters for CHRS stock.

Will CHRS stock go high in the next 2 weeks?

No, our stock forecasting algorithm shows that CHRS stock will lose-3.182432432432427 in the next 2 weeks. This prediction may vary from other time period filters for CHRS stock.

What is CHRS stock last closing price?

Last closing price of CHRS stock was $1.48.

What is CHRS stock price prediction?

CHRS stock price prediction means predicting the future closing prices of CHRS stock based on its past data. Our forecasting algorithm uses various machine learning and deep learning techniques to forecast the future behavior of CHRS stock in a certain time period.

How we predict CHRS stock future prices?

If you are searching for CHRS stock forecast, analysis or price prediction, then you might be wondering what Coherus Oncology, Inc. (CHRS) will do in the future. Our CHRS price predictions are based on various Machine Learning based algorithms with an aim to try and predict future price movements. This CHRS price prediction will likely answer most of your questions.

How frequent we update CHRS stock predictions?

We are updating the forecasts for the CHRS stock on daily basis.

Is using ML forecasting for CHRS stock a good way?

Yes. Stock Price Prediction is one of the most exciting applications of Machine Learning. By leveraging data from the past, it is possible to use forecasting models to make accurate predictions about future stock prices. This can be incredibly beneficial for investors and traders, as it gives them the ability to make more informed decisions about when to buy and sell. Investing in the stock market can be a risky endeavor, but leveraging Machine Learning can make it a bit less daunting and more profitable.

Is the Prediction for CHRS stock same for all the time periods?

No, the prediction for CHRS stock is not same for all time periods. The forecasts may vary depending on the differences in the time period.

Coherus Oncology, Inc. Stock Forecast and Stock Price Prediction

Stock Forecast Chart

Stock Price Prediction Summary

Closed Price$1.48-15.43%Since 2 Weeks

Predicted Price$1.43-3.18%For 2 Weeks

Upper Predicted Price$1.533.64%For 2 Weeks

Lower Predicted Price$1.33-9.91%For 2 Weeks

Forecast Score Based on 2 Weeks

Based on our forecast, the price of CHRS will decline by -3.18% over the next 2 Weeks and hit $1.43 by Tuesday, June 2, 2026. In that time frame, CHRS's share price is expected to range between $1.33 and $1.53.

BearishAverageBullish

Date	Predicted Lower	Predicted	Predicted Upper
Jun 2, 2026	1.33	1.43	1.53
Jun 1, 2026	1.37	1.47	1.57
May 29, 2026	1.33	1.43	1.53
May 28, 2026	1.34	1.44	1.53
May 27, 2026	1.35	1.45	1.56
May 26, 2026	1.35	1.45	1.55
May 25, 2026	1.38	1.48	1.59
May 22, 2026	1.34	1.44	1.55
May 21, 2026	1.35	1.45	1.55
May 20, 2026	1.37	1.47	1.57

CHRS shares fell -0.67% in Tuesday, May 19, 2026's trading session, dropping from a previous close of $1.49 to move at $1.48. The stock demonstrated notable intraday movement (see CHRS's key stats for a full breakdown), fluctuating between $1.46 and $1.51, a +3.08% trading range. While recent weeks have seen some volatility, CHRS has managed to secure a -15.43% drop over the past 2 weeks. The downward price movement was accompanied by decreased trading volume, with approximately 1.37M shares changing hands, 398.76K fewer than the previous session. This amounted to $2.03M in total market activity.

Will CHRS Continue Its Upward Trend?

According to analyst ratings and projections for CHRS, Coherus Oncology, Inc. shares are anticipated to increase by +3.51%, potentially reaching $1.53 per share by June 2, 2026. Short-term technical indicators currently suggest a neutral sentiment for CHRS. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 12 positive trading days within the past 30 sessions. Based on the CHRS stock forecast, now is a good time to buy CHRS stock because its current trading price is +3.29% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on CHRS covering social and institutional perspectives.

CHRS Technical Momentum: Overbought, Oversold, or Neutral?

An analysis of Relative Strength Index (RSI) indicators provides insight into CHRS's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 30.23% to 39.72%) suggest the stock is in a weak bearish momentum phase. The 50-day RSI, at 46.66%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 49.21%, maintains a neutral outlook for the long term. Insights into CHRS's shareholder base show how institutional investors are positioning themselves during these momentum shifts

Coherus Oncology Short-Term Forecasts

CHRS Forecast For Next 5 Days

Our algorithm anticipates Coherus Oncology (CHRS) stock could hit $1.60 by May 26, 2026. This represents a +8.24% fall from today's price, following a -6.06% change over the past five days.

CHRS Forecast For Next 30 Days

Based on analysis of market trends, the outlook for Coherus Oncology, Inc. (CHRS) stock over the next 30 days is largely positive. Price forecasts suggest an average target of $1.63, which would mean a +10.14% increase from the current price of $1.48. Projections for this period range from a high of $1.85 to a low of $1.40.

CHRS Forecast For Next 90 Days

Our proprietary market analysis suggests predictions for Coherus Oncology's price over the next three months point to a rise. CHRS stock is expected to peak at $8.44 on Aug 17, 2026 after potentially dipping to $4.66 on Jun 04, 2026. On average, CHRS is likely to trade around $6.34 in the coming 90 days.

Coherus Oncology Stock Forecast 2025

Based on our predictive models, Coherus Oncology (CHRS) is expected to trade between $4.66 and $11.55 throughout 2026. This would result in an average price of $7.17, potentially offering investors a +384.46% return from current levels.

Coherus Oncology, Inc. Monthly Forecast 2026–2027

May 2026

According to our latest forecast models, Coherus Oncology, Inc. (CHRS) is positioned to show a strong performance in May 2026. The price is predicted to move between $4.66 and $5.10, settling at an average of $4.87. This could translate to a +229.05% gain.

June 2026

Based on current market signals, Coherus Oncology, Inc. is projected to trend june 2026. We forecast a trading range from $4.66 to $6.30, with a likely average price of $5.62. Investors could expect a potential return of +279.73%.

July 2026

Our predictive algorithms indicate Coherus Oncology, Inc. stock may see a shift in July 2026. The expected range spans $5.33–$8.03, with an average target of $6.61. This represents a positive outlook and a possible gain of +346.62%.

August 2026

Analyzing established trends, Coherus Oncology, Inc. looks set to move in August 2026. Projections place the stock between $7.40 and $8.74, averaging around $7.95. This suggests a +437.16% gain from current levels.

September 2026

Market indicators suggest Coherus Oncology, Inc. could experience notable changes during September 2026. Prices could fluctuate within $5.87 to $8.67, with a midpoint forecast of $7.64. The stock might deliver a +416.22% gain.

October 2026

Forecasting for October 2026, models estimate that Coherus Oncology, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $5.75 and $8.83, averaging $7.47. This signals a positive trajectory with potential returns around +404.73%.

November 2026

According to our latest forecast models, Coherus Oncology, Inc. (CHRS) is positioned to show a strong performance in November 2026. The price is predicted to move between $5.63 and $7.59, settling at an average of $6.83. This could translate to a +361.49% gain.

December 2026

Based on current market signals, Coherus Oncology, Inc. is projected to trend december 2026. We forecast a trading range from $5.81 to $11.55, with a likely average price of $8.88. Investors could expect a potential return of +500.00%.

January 2027

Our predictive algorithms indicate Coherus Oncology, Inc. stock may see a shift in January 2027. The expected range spans $6.90–$12.05, with an average target of $10.42. This represents a positive outlook and a possible gain of +604.05%.

February 2027

Analyzing established trends, Coherus Oncology, Inc. looks set to move in February 2027. Projections place the stock between $5.63 and $11.26, averaging around $9.32. This suggests a +529.73% gain from current levels.

March 2027

Market indicators suggest Coherus Oncology, Inc. could experience notable changes during March 2027. Prices could fluctuate within $4.81 to $9.87, with a midpoint forecast of $8.02. The stock might deliver a +441.89% gain.

April 2027

Forecasting for April 2027, models estimate that Coherus Oncology, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $5.33 and $12.51, averaging $10.06. This signals a positive trajectory with potential returns around +579.73%.

May 2027

According to our latest forecast models, Coherus Oncology, Inc. (CHRS) is positioned to show a strong performance in May 2027. The price is predicted to move between $4.75 and $11.43, settling at an average of $9.32. This could translate to a +529.73% gain.

CHRS's history of dividends and stock splits also plays a role in long-term investor confidence.